Bacillus subtilis: The Definitive Guide

What is Bacillus subtilis?

Bacillus subtilis is a bacterium that can form dormant endospores. Those spores tolerate drying, heat and gastric acid better than many vegetative probiotic cells, which makes them useful in shelf-stable capsules and foods. After encountering suitable conditions, a spore can germinate into a metabolically active cell. Neither survival nor germination proves a health effect on its own.

Strain codes define the clinical evidence. BS50 and MB40 have both been tested for gas-related symptoms, but their randomized trials did not agree. CU1 has been studied for immune outcomes, while DE111 has small studies of lipids, immune measures and athletes. Natto is a fermented food made with B. subtilis var. natto; its complete food matrix and vitamin K content are not equivalent to a purified supplement strain. [1]

Typical Bacillus subtilis Protocols

The first two rows are especially useful because they discourage dose ranking. The negative MB40 digestive trial used a higher viable count than the positive BS50 trial. That does not make BS50 universally better; it shows that strain, study design, symptom definition and duration matter more than reading CFU as a potency scale. [2], [3]

Primary outcome

The CU1 trial’s main clinical outcome was mean days with common infectious-disease symptoms, and the between-group result was not significant. Biomarkers and a post hoc subset cannot replace it. [4]

Composite outcome

BS50 improved a combined bloating, burping and flatulence score. Burping was individually significant; bloating alone was not at the conventional threshold. [2]

Mass versus viable count

The S. aureus trial abstract reports 250 mg of MB40. Do not infer its CFU or transfer the 5-billion-CFU digestive schedule from a different MB40 formulation.

What is B. subtilis commonly used for?

Gas-related digestive symptoms

In the BS50 trial, 47.4% of active participants versus 22.2% of placebo participants improved on the three-item composite at week six; the odds ratio was 3.2 with a 95% confidence interval of 1.1 to 8.7. Burping improved in 44.7% versus 22.2%. Bloating improved in 31.6% versus 13.9%, but P=.071, so that individual comparison was not statistically significant. Other symptoms, intestinal-permeability markers, inflammation measures and plasma lipids did not meaningfully change. The strain manufacturer funded the trial, supplied products, participated in design and writing, and filed a patent related to the findings. [2]

The MB40 digestive trial is the counterweight. Among 100 randomized participants taking 5 billion CFU/day or placebo for four weeks, average weekly change did not differ for bloating intensity, days or duration, abdominal discomfort or gas. A sex-subgroup analysis suggested improvement in some measures among men, but not the full population; this subgroup result does not turn the overall trial positive. [3]

Immune outcomes

CU1 increased fecal and salivary secretory IgA in a predefined 44-person biological subset. The full 100-person group did not have significantly fewer symptom days: means were 5.1 days with CU1 and 6.6 with placebo, P=.2015. A lower respiratory-infection frequency in the subset was post hoc. The study therefore supports a biomarker signal, not a proven prevention claim. [4]

S. aureus decolonization

The 2023 phase 2 trial found stool S. aureus counts fell 96.8% and nasal counts 65.4% after 30 days of MB40, without significant microbiome disruption. Colonization is a surrogate endpoint. The trial did not show fewer skin infections, bloodstream infections, hospital admissions or antibiotic courses, so retail products should not be promoted as infection treatment on this evidence. [5]

How do you read the form and label?

Look for the exact strain code, CFU per unit and serving, the time point at which CFU is guaranteed, other organisms, prebiotic fibres, expiry, lot and storage. “Soil-based probiotic” is a marketing category, not a clinical identity. A multi-strain product cannot inherit a single-strain result unless the tested product and amounts match.

B. subtilis supplement strains can have separate FDA GRAS notices for specified food uses. The record belongs to the named preparation and conditions of use; it is not FDA approval of a disease claim. In Canada, a natural health product licence is also product-specific. Natto additionally contains food-derived compounds, including vitamin K, which can matter for warfarin users.

How should B. subtilis be stored?

Spores are generally shelf-stable, but use the finished-product instructions. Keep the container dry and closed, avoid excessive heat and respect the expiry date. A stability claim should specify the count through shelf life. Do not assume all strains tolerate the same food-processing temperature or that an opened powder remains viable indefinitely.

What does the human evidence show?

DE111 studies remain exploratory. A four-week healthy-adult trial reported within-group reductions in total and non-HDL cholesterol, but the abstract does not establish that every lipid outcome differed from placebo. A 23-athlete study found no probiotic advantage for strength or performance, although one body-fat interaction favored DE111. Neither supports a general cardiovascular or ergogenic claim. [6], [7]

What are the risks and interactions?

Gas, bloating and stool changes can occur. Product blends may add fibre or other organisms, making the responsible ingredient unclear. Stop and seek assessment for blood in stool, high fever, dehydration, severe pain, persistent vomiting, marked distension or prolonged diarrhea.

Bacillus species can cause opportunistic invasive infection in vulnerable hosts. Case reports do not establish ordinary-user incidence and may involve medical products or strains different from retail supplements. They do justify avoiding unsupervised live-spore use in critical illness, major immune suppression, central venous access, severe barrier disruption and very premature infants. The FDA has warned healthcare providers about potentially fatal invasive disease from probiotics given to hospitalized preterm infants. [1]

Antibiotic susceptibility varies by strain and drug. A fixed two-hour spacing rule has not been validated for every B. subtilis product. Do not delay prescribed antibiotics. Ask a pharmacist about the exact organism and medicine, especially when treating an active infection. Natto food can deliver substantial vitamin K and requires a separate consistency discussion with warfarin care; purified B. subtilis capsules are not automatically equivalent to natto.

What is the legal and regulatory status?

In the United States, B. subtilis products may be foods or dietary supplements. GRAS notices address specified food uses, not treatment approval. In Canada, licensed natural health products carry product-specific claims and conditions. Neither framework makes “spore probiotic” an approved treatment category.

What happens when you stop?

B. subtilis is not known to produce drug-like withdrawal. Fecal detection after stopping can reflect transient passage, germination and re-sporulation, not permanent colonization. A returning symptom may reflect diet, the original condition, another product ingredient or natural variation.

What should you monitor?

Select a primary outcome before use: bloating days, burping episodes, abdominal-discomfort score or stool form. Record a one-to-two-week baseline and note diet, fermentable fibre, antibiotics, laxatives and product changes. Review the exact study window, such as six weeks for BS50, rather than importing a faster timeline from another strain or a mechanistic study.

What does community experience add?

Public reports can surface capsule tolerance, early gas, refrigeration confusion and blend-specific reactions. They rarely verify the strain or distinguish B. subtilis from other organisms and fibres. No systematic current community sample was assembled for this refresh, so no consensus score or frequency estimate is reported.

How do nearby spore probiotics compare?

Common questions

Is B. subtilis the same as natto?

No. Natto is a fermented soybean food with a complete food matrix and vitamin K. A capsule strain and a food serving are not interchangeable.

Did BS50 reduce bloating?

The combined bloating-burping-flatulence outcome improved, as did burping alone. The individual bloating comparison had P=.071 and was not significant at .05. [2]

Did MB40 fail completely?

It did not improve the main digestive outcomes in a 100-person trial. A separate trial found a large reduction in S. aureus colonization, a different endpoint. [3], [5]

Does CU1 prevent winter infections?

The full trial did not significantly reduce mean infectious-symptom days. IgA changed in a subset, and the respiratory-frequency result was post hoc. [4]

Are more CFU better?

No dose-response conclusion follows from these studies. The negative digestive trial used more CFU than the positive BS50 trial.

Glossary

Plain explanations of the probiotic research terms used here.

Endospore

A dormant, resistant bacterial form that can later germinate under suitable conditions.

CFU

Colony-forming unit, an estimate of viable microorganisms.

Composite outcome

A prespecified result combining more than one measure, such as bloating, burping and flatulence.

Post hoc analysis

An analysis selected after or outside the main plan and more vulnerable to chance findings.

Surrogate outcome

A measure such as bacterial colonization used in place of a direct health outcome such as infection.

How this guide was researched

NIH ODS guidance defined the strain-specific framework. Primary trial records supplied exact BS50, MB40 and CU1 schedules, populations, outcomes, sponsor disclosures and analysis limits. Positive findings were kept beside the negative MB40 digestive trial and negative CU1 primary outcome. Colonization and blood-marker changes were not converted into infection, cardiovascular or performance benefits.

Explore the sources

Related guides

• Bacillus coagulans
• Bifidobacterium
• Lactobacillus
• Saccharomyces boulardii

Editorial note

This guide preserves the negative MB40 digestive trial, the negative CU1 primary outcome, the BS50 sponsor disclosure and the boundary between colonization and infection. It was authored in English for translation from the same evidence record.